|
Imatinib mesylate (GLEEVEC((R)), GLIVEC((R)), formerly STI571) has
demonstrated unprecedented efficacy as first line therapy for treatment for all
phases of chronic myelogenous leukemia (CML) and metastatic and unresectable
malignant gastrointestinal stromal tumors (GIST). Disposition and
biotransformation of imatinib were studied in four male healthy volunteers after
a single oral dose of 239 mg (14)C-labeled imatinib mesylate.
New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com CML (Chronic Myelogenous Leukemia Support List) --------------------------------- Part Of CMLHope.Com An International Community Of CML Patients For more information: http://cmlhope.com Post Message: [email protected] Subscribe: [EMAIL PROTECTED] Unsubscribe: [EMAIL PROTECTED] Change To No Mail/Web: [EMAIL PROTECTED] Change To Digest: [EMAIL PROTECTED] Change To Email: [EMAIL PROTECTED] List Help: [EMAIL PROTECTED] CML Group Web Site http://groups.yahoo.com/group/CML ---- LSpots keywords ?> ---- HM ADS ?> YAHOO! GROUPS LINKS
|
